Innate Pharma S.A. (IPHA)

Innate Pharma Revenue

Innate Pharma had revenue of 12.35M EUR in the half year ending June 30, 2024, a decrease of -72.92%. This brings the company's revenue in the last twelve months to 33.79M, down -35.37% year-over-year. In the year 2023, Innate Pharma had annual revenue of 61.64M with 6.88% growth.

• Revenue (ttm): 33.79M EUR
• Revenue Growth: -35.37%
• P/S Ratio: 5.32
• Revenue / Employee: 188,760 EUR
• Employees: 179
• Market Cap: 192.71M USD

Revenue Chart

* This company reports financials in EUR.

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2023	61.64M	3.97M	6.88%
Dec 31, 2022	57.67M	32.97M	133.47%
Dec 31, 2021	24.70M	-45.07M	-64.60%
Dec 31, 2020	69.77M	-15.68M	-18.35%
Dec 31, 2019	85.45M	-8.50M	-9.05%

Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.